European Union:
CHMP Recommends Extensions For Seven Therapeutic Indications
12 November 2015
Jones Day
To print this article, all you need is to be registered or login on Mondaq.com.
During its October 19–22, 2015 meetings, the Committee for
Medicinal Products for Human Use ("CHMP") recommended
extensions of indication for Cubicin, Edurant,
Emend, Volibris, Xalkori, and two extensions of indication for
Cosentyx.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
POPULAR ARTICLES ON: Food, Drugs, Healthcare, Life Sciences from European Union
Healthcare Policy Developments To Watch In 2024
Crowell & Moring LLP
The ever-changing healthcare policy landscape will witness at the federal level regulatory changes driven by the need to transform healthcare delivery, quality and innovation.
The FDA And The Future Of AI Oversight
Manatt, Phelps & Phillips LLP
In January 2024, the U.S. Government Accountability Office (GAO) issued a report highlighting current obstacles to the U.S. Food and Drug Administration's (FDA) timely and effective regulation...